ArticleLeukemia2008
Dose-dependent repression of T-cell and natural killer cell genes by PU.1 enforces myeloid and B-cell identity.
Article in Leukemia, 2008. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 23 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
23 citing papers in PubMed, 42 citations in OpenAlex.
- HDAC1 and PRC2 mediate combinatorial control in SPI1/PU.1-dependent gene repression in murine erythroleukaemia.Nucleic acids research · 2022Article
- Logic and lineage impacts on functional transcription factor deployment for T-cell fate commitment.Biophysical journal · 2021Review
- Modest changes in Spi1 dosage reveal the potential for altered microglial function as seen in Alzheimer's disease.Scientific reports · 2021Article
- PU.1 drives specification of pluripotent stem cell-derived endothelial cells to LSEC-like cells.Cell death & disease · 2021Article
- Lineage Decision-Making within Normal Haematopoietic and Leukemic Stem Cells.International journal of molecular sciences · 2020Review
- A general computational approach to predicting synergistic transcriptional cores that determine cell subpopulation identities.Nucleic acids research · 2019Article
- Transcription Factor PU.1 Represses and Activates Gene Expression in Early T Cells by Redirecting Partner Transcription Factor Binding.Immunity · 2018Article
- Environmental sensing by mature B cells is controlled by the transcription factors PU.1 and SpiB.Nature communications · 2017Article
- Coordination of Myeloid Differentiation with Reduced Cell Cycle Progression by PU.1 Induction of MicroRNAs Targeting Cell Cycle Regulators and Lipid Anabolism.Molecular and cellular biology · 2017Article
- Myeloid-derived NF-κB negative regulation of PU.1 and c/EBP-β-driven pro-inflammatory cytokine production restrains LPS-induced shock.Innate immunity · 2017Article
- IL-32θ: a recently identified anti-inflammatory variant of IL-32 and its preventive role in various disorders and tumor suppressor activity.American journal of translational research · 2017Review
- Hematopoiesis and T-cell specification as a model developmental system.Immunological reviews · 2016Review
- Regulation of early T-lineage gene expression and developmental progression by the progenitor cell transcription factor PU.1.Genes & development · 2015Article
- PU.1 downregulation in murine radiation-induced acute myeloid leukaemia (AML): from molecular mechanism to human AML.Carcinogenesis · 2015Review
- Positive feedback between PU.1 and the cell cycle controls myeloid differentiation.Science (New York, N.Y.) · 2013Article
- Spi-1/PU.1 activates transcription through clustered DNA occupancy in erythroleukemia.Nucleic acids research · 2012Article
- A dose-dependent role for EBF1 in repressing non-B-cell-specific genes.European journal of immunology · 2011Article
- Molecular mechanisms influencing NK cell development: implications for NK cell malignancies.American journal of blood research · 2011Article
- The Transcription Factor NURR1 Exerts Concentration-Dependent Effects on Target Genes Mediating Distinct Biological Processes.Frontiers in neuroscience · 2011Article
- PU.1 and Haematopoietic Cell Fate: Dosage Matters.International journal of cell biology · 2011Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors at 3 institutions in 1 country.
Funding
Abstract
The Ets transcription factor PU.1, encoded by the gene Sfpi1, functions in a concentration-dependent manner to promote myeloid and B-cell development and has been implicated in myeloid and lymphoid leukemias. To determine the consequences of reducing PU.1 concentration during hematopoiesis, we analyzed mice with two distinct hypomorphic alleles of Sfpi1 that produce PU.1 at approximately 20% (BN) or approximately 2% (Blac) of wild-type levels. Myeloid development was impaired in these mice, but less severely than in Sfpi1 null mice. To identify the downstream target genes that respond to changes in PU.1 concentration, we analyzed ex vivo interleukin-3 dependent myeloid cell lines established from Sfpi1(BN/BN), Sfpi1(Blac/Blac) and Sfpi1(-/-) fetal liver cells. Unexpectedly, many T-cell and natural killer cell genes were expressed in Sfpi1(-/-) cells and repressed in a dose-dependent manner in Sfpi1(Blac/Blac) and Sfpi1(BN/BN) cells. This pattern of dose-dependent T/NK-cell gene repression also occurred in ex vivo interleukin-7 dependent progenitor B cell lines. These results suggest that PU.1 functions in a concentration-dependent manner to repress T-cell and natural killer cell fates while promoting myeloid and B-cell fates.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.